Immunomonitoring of nuclear factor of activated T cells-regulated gene expression: The first clinical trial in liver allograft recipients

Liver Transplantation

Volumn 17, Issue 4, 2011, Pages 466-473

  Zahn, Alexandra ^a   Schott, Nadja ^a   Hinz, Ulf ^a   Stremmel, Wolfgang ^a   Schmidt, Jan ^a   Ganten, Tom ^a   Gotthardt, Daniel ^a   Meuer, Stefan ^b   Zeier, Martin ^a   Giese, Thomas ^b   Sommerer, Claudia ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; TACROLIMUS; TRANSCRIPTION FACTOR NFAT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DRUG EFFICACY; DRUG MONITORING; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; INFECTION; LIVER GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEOPLASM; NEPHROTOXICITY; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; CALCINEURIN; CYCLOSPORINE; DRUG MONITORING; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIVER TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NFATC TRANSCRIPTION FACTORS; PILOT PROJECTS; T-LYMPHOCYTES; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 79953167881     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22254     Document Type: Article

References (34)

1. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D,. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612. (Pubitemid 30118412)
2. Buell JF, Gross TG, Woodle ES,. Malignancy after transplantation. Transplantation 2005; 80 (2 Suppl): S254-S264. (Pubitemid 41552912)
3. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD,. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78: 557-565. (Pubitemid 39097102)
4. Fernandez-Marmiesse A, Hermida J, Tutor JC,. Comparison of predose vs 2-h postdose blood metabolites/cyclosporine ratios in kidney and liver transplant patients. Clin Biochem 2000; 33: 383-386.
5. Morris RG, Russ GR, Cervelli MJ, Juneja R, McDonald SP, Mathew TH,. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 2002; 24: 479-486. (Pubitemid 34857899)
6. Kovarik JM, Mueller EA, van Bree JB, Fluckiger SS, Lange H, Schmidt B, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation-a multicenter investigation in kidney transplant patients. Transplantation 1994; 58: 658-663. (Pubitemid 24317763)
7. Barnard JB, Thekkudan J, Richardson S, Bittar MN, Martyszczuck R, Hasan J, et al. Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation. J Heart Lung Transplant 2006; 25: 564-568.
8. Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R,. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 1998; 12: 243-249. (Pubitemid 28269248)
9. Marin JG, Levine M, Ensom MH,. Is C2 monitoring or another limited sampling strategy superior to C0 monitoring in improving clinical outcomes in adult liver transplant recipients? Ther Drug Monit 2006; 28: 637-642. (Pubitemid 44564062)
10. Cambaceres CG, Rojas L, Fernandez MC, Licciardone N, Ferreira O, Diaz A, et al. Monitoring cyclosporine microemulsion at two hours post dosing in pediatric maintenance liver transplant recipients. Transplant Proc 2010; 42: 361-362.
11. Furlan V, Lykavieris P, Maubert MA, Habes D, Debray D,. Rationale for monitoring cyclosporine concentration at 2 hours after administration in infants posttransplantation. Transplant Proc 2009; 41: 3333-3334.
12. Giese T, Zeier M, Schemmer P, Uhl W, Schoels M, Dengler T, et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation 2004; 77: 339-344. (Pubitemid 38209728)
13. Sommerer C, Konstandin M, Dengler T, Schmidt J, Meuer S, Zeier M, Giese T,. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 2006; 82: 1280-1285. (Pubitemid 44832909)
14. Konstandin MH, Sommerer C, Doesch A, Zeier M, Meuer SC, Katus HA, et al. Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients. Transpl Int 2007; 20: 1036-1043. (Pubitemid 350043847)
15. Giese T, Zeier M, Meuer S,. Analysis of NFAT-regulated gene expression in vivo: a novel perspective for optimal individualized doses of calcineurin inhibitors. Nephrol Dial Transplant 2004; 19 (suppl 4): iv55-iv60. (Pubitemid 39136707)
16. Sommerer C, Hartschuh W, Enk A, Meuer S, Zeier M, Giese T,. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients. Clin Transplant 2008; 22: 549-554.
17. Sommerer C, Giese T, Schmidt J, Meuer S, Zeier M,. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression. Transplantation 2008; 85: 15-21.
18. Sommerer C, Zeier M, Meuer S, Giese T,. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. Transplantation 2010; 89: 1417-1423.
19. Opelz G, Dohler B,. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009; 87: 795-802.
20. Jiang H, Kobayashi M,. Differences between cyclosporin A and tacrolimus in organ transplantation. Transplant Proc 1999; 31: 1978-1980. (Pubitemid 29376498)
21. Almawi WY, Melemedjian OK,. Clinical and mechanistic differences between FK506 (tacrolimus) and cyclosporin A. Nephrol Dial Transplant 2000; 15: 1916-1918.
22. Elbaz B, Alperovitch A, Gottesman MM, Kimchi-Sarfaty C, Rahamimoff H,. Modulation of Na+-Ca2+ exchanger expression by immunosuppressive drugs is isoform-specific. Mol Pharmacol 2008; 73: 1254-1263. (Pubitemid 351439207)
23. Neil DA, Hübscher SG,. Current views on rejection pathology in liver transplantation. Transpl Int 2010; 23: 971-983.
24. Cakaloglu Y, Devlin J, O'Grady J, Sutherland S, Portmann BC, Heaton N, et al. Importance of concomitant viral infection during late acute liver allograft rejection. Transplantation 1995; 59: 40-45.
25. Anand AC, Hubscher SG, Gunson BK, McMaster P, Neuberger JM,. Timing, significance, and prognosis of late acute liver allograft rejection. Transplantation 1995; 60: 1098-1103.
26. Ramji A, Yoshida EM, Bain VG, Kneteman NM, Scudamore CH, Ma MM, et al. Late acute rejection after liver transplantation: the Western Canada experience. Liver Transpl 2002; 8: 945-951. (Pubitemid 35154027)
27. Naesens M, Kuypers DR, Sarwal M,. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481-508.
28. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y,. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007; 82: 711-725. (Pubitemid 350114816)
29. Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Katafuchi R, Hirakata H, et al. Risk factors for renal glomerular and vascular changes in an autopsy-based population survey: the Hisayama study. Kidney Int 2003; 63: 1508-1515. (Pubitemid 36350017)
30. Hocherl K, Kees F, Kramer BK, Kurtz A,. Cyclosporine A attenuates the natriuretic action of loop diuretics by inhibition of renal COX-2 expression. Kidney Int 2004; 65: 2071-2080. (Pubitemid 38669993)
31. Sturrock ND, Lang CC, Struthers AD,. Indomethacin and cyclosporin together produce marked renal vasoconstriction in humans. J Hypertens 1994; 12: 919-924. (Pubitemid 24283375)
32. Soubhia RM, Mendes GE, Mendonca FZ, Baptista MA, Cipullo JP, Burdmann EA,. Tacrolimus and nonsteroidal anti-inflammatory drugs: an association to be avoided. Am J Nephrol 2005; 25: 327-334. (Pubitemid 41160991)
33. van de Wetering J, Weimar CH, Balk AH, Roodnat JI, Holweg CT, Baan CC, et al. The impact of transforming growth factor-beta1 gene polymorphism on end-stage renal failure after heart transplantation. Transplantation 2006; 82: 1744-1748. (Pubitemid 46035662)
34. Abdi R, Tran TB, Zee R, Brenner BM, Milford EL,. Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension. Transplantation 2001; 72: 726-729. (Pubitemid 32802760)